Mesenchymal Stem Cells in Systemic Sclerosis: Allogenic or Autologous Approaches for Therapeutic Use?
Systemic sclerosis (SSc) is a rare autoimmune disease, which is potentially lethal. The physiopathology of the disease is still incompletely elucidated although the role of fibroblasts, endothelial cells (ECs), immune cells. and the environment (i.e., oxidative stress) has been demonstrated. This is...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2018-12-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2018.02938/full |
| _version_ | 1818544098244558848 |
|---|---|
| author | Pauline Rozier Pauline Rozier Alexandre Maria Alexandre Maria Radjiv Goulabchand Radjiv Goulabchand Christian Jorgensen Christian Jorgensen Philippe Guilpain Philippe Guilpain Danièle Noël Danièle Noël |
| author_facet | Pauline Rozier Pauline Rozier Alexandre Maria Alexandre Maria Radjiv Goulabchand Radjiv Goulabchand Christian Jorgensen Christian Jorgensen Philippe Guilpain Philippe Guilpain Danièle Noël Danièle Noël |
| author_sort | Pauline Rozier |
| collection | DOAJ |
| description | Systemic sclerosis (SSc) is a rare autoimmune disease, which is potentially lethal. The physiopathology of the disease is still incompletely elucidated although the role of fibroblasts, endothelial cells (ECs), immune cells. and the environment (i.e., oxidative stress) has been demonstrated. This is an intractable disease with an urgent need to provide better therapeutic options to patients. Mesenchymal stem cells (MSCs) represent a promising therapeutic approach thanks to the number of trophic and pleiotropic properties they exert. Among these, MSCs display anti-fibrotic, angiogenic, and immunomodulatory capacities that might be of interest in the treatment of SSc by acting on different processes that are dysregulated in the disease. In the recent years, the therapeutic effectiveness of MSCs has been demonstrated in different preclinical animal models and is being investigated in phase I clinical trials. Both allogenic and autologous transplantation of MSCs isolated from bone marrow or adipose tissue is being evaluated. The rationale for using allogenic MSCs in SSc, as well as in other autoimmune diseases, is based on the possibility that autologous MSCs might be altered in these diseases. In SSc, reports from the literature are controversial. Nevertheless, the role of the oxidative environment and of the crosstalk with neighboring cells (fibroblasts and ECs) on the functional properties of MSCs has been reported. Here, we review the preclinical and clinical data reporting the interest of MSC-based treatment in SSc and question the use of autologous or allogeneic MSCs in perspective of clinical applications. |
| first_indexed | 2024-12-11T22:44:00Z |
| format | Article |
| id | doaj.art-2567041b57484f59bc0082b102a02b16 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-11T22:44:00Z |
| publishDate | 2018-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-2567041b57484f59bc0082b102a02b162022-12-22T00:47:41ZengFrontiers Media S.A.Frontiers in Immunology1664-32242018-12-01910.3389/fimmu.2018.02938416030Mesenchymal Stem Cells in Systemic Sclerosis: Allogenic or Autologous Approaches for Therapeutic Use?Pauline Rozier0Pauline Rozier1Alexandre Maria2Alexandre Maria3Radjiv Goulabchand4Radjiv Goulabchand5Christian Jorgensen6Christian Jorgensen7Philippe Guilpain8Philippe Guilpain9Danièle Noël10Danièle Noël11IRMB, Univ Montpellier, INSERM, CHU Montpellier, Montpellier, FranceDepartment of Internal Medicine, Multiorganic Diseases, Saint-Eloi Hospital, Montpellier, FranceIRMB, Univ Montpellier, INSERM, CHU Montpellier, Montpellier, FranceDepartment of Internal Medicine, Multiorganic Diseases, Saint-Eloi Hospital, Montpellier, FranceIRMB, Univ Montpellier, INSERM, CHU Montpellier, Montpellier, FranceDepartment of Internal Medicine, Multiorganic Diseases, Saint-Eloi Hospital, Montpellier, FranceIRMB, Univ Montpellier, INSERM, CHU Montpellier, Montpellier, FranceClinical Immunology and Osteoarticular Diseases Therapeutic Unit, Lapeyronie University Hospital, Montpellier, FranceIRMB, Univ Montpellier, INSERM, CHU Montpellier, Montpellier, FranceDepartment of Internal Medicine, Multiorganic Diseases, Saint-Eloi Hospital, Montpellier, FranceIRMB, Univ Montpellier, INSERM, CHU Montpellier, Montpellier, FranceClinical Immunology and Osteoarticular Diseases Therapeutic Unit, Lapeyronie University Hospital, Montpellier, FranceSystemic sclerosis (SSc) is a rare autoimmune disease, which is potentially lethal. The physiopathology of the disease is still incompletely elucidated although the role of fibroblasts, endothelial cells (ECs), immune cells. and the environment (i.e., oxidative stress) has been demonstrated. This is an intractable disease with an urgent need to provide better therapeutic options to patients. Mesenchymal stem cells (MSCs) represent a promising therapeutic approach thanks to the number of trophic and pleiotropic properties they exert. Among these, MSCs display anti-fibrotic, angiogenic, and immunomodulatory capacities that might be of interest in the treatment of SSc by acting on different processes that are dysregulated in the disease. In the recent years, the therapeutic effectiveness of MSCs has been demonstrated in different preclinical animal models and is being investigated in phase I clinical trials. Both allogenic and autologous transplantation of MSCs isolated from bone marrow or adipose tissue is being evaluated. The rationale for using allogenic MSCs in SSc, as well as in other autoimmune diseases, is based on the possibility that autologous MSCs might be altered in these diseases. In SSc, reports from the literature are controversial. Nevertheless, the role of the oxidative environment and of the crosstalk with neighboring cells (fibroblasts and ECs) on the functional properties of MSCs has been reported. Here, we review the preclinical and clinical data reporting the interest of MSC-based treatment in SSc and question the use of autologous or allogeneic MSCs in perspective of clinical applications.https://www.frontiersin.org/article/10.3389/fimmu.2018.02938/fullmesenchymal stem cellsystemic sclerosisallogeniccell therapybleomycinHOCl |
| spellingShingle | Pauline Rozier Pauline Rozier Alexandre Maria Alexandre Maria Radjiv Goulabchand Radjiv Goulabchand Christian Jorgensen Christian Jorgensen Philippe Guilpain Philippe Guilpain Danièle Noël Danièle Noël Mesenchymal Stem Cells in Systemic Sclerosis: Allogenic or Autologous Approaches for Therapeutic Use? Frontiers in Immunology mesenchymal stem cell systemic sclerosis allogenic cell therapy bleomycin HOCl |
| title | Mesenchymal Stem Cells in Systemic Sclerosis: Allogenic or Autologous Approaches for Therapeutic Use? |
| title_full | Mesenchymal Stem Cells in Systemic Sclerosis: Allogenic or Autologous Approaches for Therapeutic Use? |
| title_fullStr | Mesenchymal Stem Cells in Systemic Sclerosis: Allogenic or Autologous Approaches for Therapeutic Use? |
| title_full_unstemmed | Mesenchymal Stem Cells in Systemic Sclerosis: Allogenic or Autologous Approaches for Therapeutic Use? |
| title_short | Mesenchymal Stem Cells in Systemic Sclerosis: Allogenic or Autologous Approaches for Therapeutic Use? |
| title_sort | mesenchymal stem cells in systemic sclerosis allogenic or autologous approaches for therapeutic use |
| topic | mesenchymal stem cell systemic sclerosis allogenic cell therapy bleomycin HOCl |
| url | https://www.frontiersin.org/article/10.3389/fimmu.2018.02938/full |
| work_keys_str_mv | AT paulinerozier mesenchymalstemcellsinsystemicsclerosisallogenicorautologousapproachesfortherapeuticuse AT paulinerozier mesenchymalstemcellsinsystemicsclerosisallogenicorautologousapproachesfortherapeuticuse AT alexandremaria mesenchymalstemcellsinsystemicsclerosisallogenicorautologousapproachesfortherapeuticuse AT alexandremaria mesenchymalstemcellsinsystemicsclerosisallogenicorautologousapproachesfortherapeuticuse AT radjivgoulabchand mesenchymalstemcellsinsystemicsclerosisallogenicorautologousapproachesfortherapeuticuse AT radjivgoulabchand mesenchymalstemcellsinsystemicsclerosisallogenicorautologousapproachesfortherapeuticuse AT christianjorgensen mesenchymalstemcellsinsystemicsclerosisallogenicorautologousapproachesfortherapeuticuse AT christianjorgensen mesenchymalstemcellsinsystemicsclerosisallogenicorautologousapproachesfortherapeuticuse AT philippeguilpain mesenchymalstemcellsinsystemicsclerosisallogenicorautologousapproachesfortherapeuticuse AT philippeguilpain mesenchymalstemcellsinsystemicsclerosisallogenicorautologousapproachesfortherapeuticuse AT danielenoel mesenchymalstemcellsinsystemicsclerosisallogenicorautologousapproachesfortherapeuticuse AT danielenoel mesenchymalstemcellsinsystemicsclerosisallogenicorautologousapproachesfortherapeuticuse |